Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02246647 · ClinicalTrials.gov registry record
Biomarkers for Intestinal Permeability in Patients With Constipation
A clinical trial of Constipation and Irritable Bowel Syndrome, sponsored by Mayo Clinic.
- Completed
- Registry status
- 39
- Enrollment target
- 1
- Study location
NCT02246647: Completed study of Constipation and Irritable Bowel Syndrome, sponsored by Mayo Clinic.
NCT02246647 is a study of Constipation and Irritable Bowel Syndrome that has completed, run by Mayo Clinic. The registered enrollment target is 39 participants, below the 205-participant average among 54 other Constipation trials with a reported enrollment target (81% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02246647, a study of Constipation and Irritable Bowel Syndrome, has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- 39 participants
- Enrollment target
- 1
- Study location
Study Summary
Our overall objective with this study is firstly to provide a comprehensive assessment of intestinal permeability, mucosal barrier function using existing biomarkers and secondly to explore novel biomarkers for measuring intestinal permeability in patients with constipation predominant Irritable Bowel Syndrome (IBS-C).
Primary Outcome
In vivo measurement of intestinal permeability using 13C mannitol \& lactulose was used. High performance liquid chromatography-tandem mass spectrometry was used to measure concentrations calculated using the overall urine volume excreted in each interval. Concentrations of 13C adjusted for the % of 13C in 12C mannitol (4.98% of 12C mannitol excreted was subtracted from 13C mannitol values; determined by analyzing replicate samples of control urine). All lactulose or 13C mannitol concentrations
Conditions Studied
Interventions
- PROCEDURE Esophagogastroduodenoscopy
- PROCEDURE Flexible sigmoidoscopy
- DIAGNOSTIC_TEST Permeability measurement
Study Locations (1)
Minnesota
- Mayo Clinic in Rochester - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 39 participants |
| Start Date | 2014-09 |
| Est. Completion | 2016-12-08 |
What the finished NCT02246647 record still lists
NCT02246647 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 39 participants, a relatively small participant target, below the 205-participant average among 54 other Constipation trials with a reported enrollment target (81% lower).
The record links to 3 conditions, with Constipation appearing as the primary indexed condition, and to 3 interventions - of which Esophagogastroduodenoscopy is the first listed.
NCT02246647 reports a single indexed study location in Minnesota.
Frequently Asked Questions
What is clinical trial NCT02246647 about?
NCT02246647 is a clinical study titled "Biomarkers for Intestinal Permeability in Patients With Constipation". Our overall objective with this study is firstly to provide a comprehensive assessment of intestinal permeability, mucosal barrier function using existing biomarkers and secondly to explore novel biomarkers for measuring intestinal permeability in patients with constipation predominant Irritable Bow...
What is the current status of trial NCT02246647?
This trial is currently completed. The enrollment target is 39 participants. The study started on 2014-09. Estimated completion is 2016-12-08.
What conditions does trial NCT02246647 study?
This clinical trial studies the following conditions: Constipation, Irritable Bowel Syndrome, Intestinal Diseases.
What interventions are being tested in trial NCT02246647?
The interventions under investigation include: Esophagogastroduodenoscopy (PROCEDURE), Flexible sigmoidoscopy (PROCEDURE), Permeability measurement (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT02246647?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02246647 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Constipation
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02246647's enrollment target sits among peer trials
39 39th of 54 higher than 16 of 54 other Constipation trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Constipation trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of Microbiome Transplantation for the Treatment of Constipation and/or Significant Bloating in Patients With Systemic Sclerosis
RECRUITING · Phase 2
-
Optimization of Postoperative Bowel Habits
RECRUITING · NA
-
Pyridostigmine for the Treatment of Constipation in Parkinson Disease
RECRUITING · Phase 2
-
Indiana University Gastrointestinal Motility Diagnosis Registry
RECRUITING
-
Assessing Tenapanor as a Treatment of CF-related Constipation.
RECRUITING · Phase 3
-
Management of Dyssynergic Defecation
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03465592 · 39 participants · Phase 1
Trial of Nivolumab Following Partially Human Leukocyte Antigen (HLA) Mismatched BMT in Children & Adults With Sarcoma
- NCT03961776 · 39 participants
Monitoring Treatment Response With On-board DWI During Neo-adjuvant Chemo-radiation for Rectal Cancer Using Magnetic Resonance-guided-radiotherapy Systems
- NCT04050280 · 39 participants · Phase 2
CLAG-GO for Patients With Persistent, Relapsed or Refractory AML
- NCT04190862 · 39 participants · Phase 1
E-CEL UVEC as an Adjunct Cell Therapy for Treatment of Anal Fistulas
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia